EICHOR
● Recruiting
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Condition: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) · Sponsor: The First Affiliated Hospital with Nanjing Medical University
About this study
This is an open-label, multicenter, phase 2, non-randomized study aiming to study the efficacy and safety of fixed-duration venetoclax consolidation in CLL patients who are on BTK inhibitor monotherapy. Patients who are on BTK inhibitor monotherapy for ≥ 6 months and still responsive are included. The study includes patients who are treatment-naive before taking BTK inhibitors. Patients will be treated with the BTK inhibitor plus full-dose venetoclax for 12 cycles after a standard 5-week dose ramp-up. Peripheral blood and bone marrow MRD status will be evaluated during and after the treatment. After the completion of combination therapy, patients will stop both BTK inhibitor and venetoclax and be followed.
This description comes directly from the study's public registry record.
Talk to the study team
Jianyong Li, PhD, MD · 86-13951877733 · lijianyonglm@126.com
Huayuan Zhu, PhD, MD · 86-13813810650 · huayuan.zhu@hotmail.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06958705